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Abstract
Background: Nitrite is a nitric oxide (NO) metabolite in tissues and blood, which can be converted to NO under hypoxia to
facilitate tissue perfusion. Although nitrite is known to cause vasodilation following its reduction to NO, the effect of nitrite
on platelet activity remains unclear. In this study, the effect of nitrite and nitrite+erythrocytes, with and without
deoxygenation, on platelet activity was investigated.
Methodology/Finding: Platelet aggregation was studied in platelet-rich plasma (PRP) and PRP+erythrocytes by
turbidimetric and impedance aggregometry, respectively. In PRP, DEANONOate inhibited platelet aggregation induced
by ADP while nitrite had no effect on platelets. In PRP+erythrocytes, the inhibitory effect of DEANONOate on platelets
decreased whereas nitrite at physiologic concentration (0.1 mM) inhibited platelet aggregation and ATP release. The effect
of nitrite+erythrocytes on platelets was abrogated by C-PTIO (a membrane-impermeable NO scavenger), suggesting an NO-
mediated action. Furthermore, deoxygenation enhanced the effect of nitrite as observed from a decrease of P-selectin
expression and increase of the cGMP levels in platelets. The ADP-induced platelet aggregation in whole blood showed
inverse correlations with the nitrite levels in whole blood and erythrocytes.
Conclusion: Nitrite alone at physiological levels has no effect on platelets in plasma. Nitrite in the presence of erythrocytes
inhibits platelets through its reduction to NO, which is promoted by deoxygenation. Nitrite may have role in modulating
platelet activity in the circulation, especially during hypoxia.
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Introduction
Nitrite is recognized as a bioactive NO metabolite and is
involved in the regulation of vascular tone by induction of
vasodilation during ischemia. The effect of nitrite appears to be
mediated through NO which activates soluble guanylyl cyclase to
produce cGMP, leading to vasodilation [1,2]. The nitrite
reductase activity of deoxygenated heme-containing proteins
especially hemoglobin, and other pathways including the reactions
of xanthine oxidoreductase under hypoxia and acidosis are
believed to be responsible for the reduction of nitrite to NO,
which contributes to the mechanism of hypoxic vasodilation
[3,4,5].
In addition to vasodilation, NO inhibits platelet reactivity [6].
The effect of NO on platelets is mediated through the activation of
guanylyl cyclase to produce cGMP [7]. Although the vasodilatory
effect of nitrite has been widely studied, the effect of nitrite on
platelet activity has received little attention. Nitrite at high
concentration (500 mM) was reported to inhibit ADP-induced
platelet aggregation and increase the cGMP levels in plasma [8].
This effect of nitrite on platelets is likely to be through NO and the
subsequent activation of guanylyl cyclase. The elevation of plasma
nitrite levels after the ingestion of nitrate-rich diet reduces the
blood pressure and attenuates the platelet aggregation induced by
ADP and collagen in plasma, suggesting a possible physiological
role of nitrite on platelet activity [9]. Nevertheless, any
contribution of the expected effect of erythrocytes and deoxygen-
ation on the action of physiological levels of nitrite on platelets
remains to be elucidated.
We hypothesized that the effects of nitrite on platelets would
require erythrocytes and that these effects could be enhanced by
the deoxygenation of erythrocytes. By using the impedance
aggregometry and flow cytometric measurement of P-selectin
expression, we demonstrate the inhibitory effect of nitrite+ery-
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blood and the ADP-induced platelet aggregation in whole blood is
also shown. However, erythrocytes also have ability to destroy NO
and this leads to apparent contradictory effects of nitrite and NO
donors on platelet aggregation.
Results
Nitrite had no effect on platelet aggregation in PRP
Nitrite even at the supraphysiologic concentrations up to
100 mM incubated in PRP for 5 min did not inhibit platelet
aggregation induced by ADP or collagen (Figure 1A). In contrast,
DEANONOate inhibited ADP-induced platelet aggregation
(Figure 1B). 200 mM C-PTIO (an NO scavenger) [10] blocked
the effect of 1 mM DEANONOate (Figure 1C). Co-incubation of
ascorbic acid, a reducing agent even at concentrations up to
1 mM, with nitrite did not inhibit aggregation in PRP (data not
shown).
Effects of erythrocytes on inhibition by nitrite and
DEANONOate of platelet aggregation and ATP release
Because erythrocytes could contribute to nitrite reduction to
NO [11], we tested whether an inhibition of aggregation would be
observed after addition of erythrocytes to PRP. The impedance
aggregometry method was used for the mixtures of PRP+ery-
throcytes because the erythrocytes interfered with the turbidimet-
ric method. In this condition, 10–20 mM ADP produced the
maximal aggregation (Figure 2A); thus, we used 20 mM ADP in
the subsequent experiments of PRP+erythrocytes. In the absence
of nitrite, platelet aggregation was not different among PRP+er-
ythrocytes at 0, 1, 10 and 20% hematocrits (Figure 2B).
The incubation of nitrite (0.01–10 mM) in PRP+erythrocytes
(20% hematocrit) decreased ADP-induced platelet aggregation. In
PRP+erythrocytes at 20% hematocrit, nitrite at 0.1–10 mM
inhibited aggregation significantly (EC50=1.360.6 mM, maxi-
mum inhibition=26.762.7%) (Figure 2C). 200 mM C-PTIO
inhibited the effect of nitrite+erythrocytes on platelet aggregation.
C-PTIO alone had no effect on platelet aggregation induced by
ADP. In PRP+erythrocytes at 20% hematocrit, nitrite at
physiologic concentration (0.1 mM) decreased platelet aggregation
from 19.060.3 to 15.960.9 V (P,0.05 compared with the value
at 0% hematocrit) (Figure 2D). Thus, the effect of 0.1 mM nitrite
was dependent on the hematocrit.
The effect of nitrite on platelet aggregation induced by collagen
and U46619 (thromboxane A2 agonist) was also examined. Similar
to the ADP experiments, nitrite alone did not inhibit platelet
aggregation induced by collagen or U46619 in plasma; however,
in the presence of erythrocytes (20% hematocrit), 0.1 mM nitrite
inhibited platelet aggregation. In addition, the effect of nitrite was
diminished in the presence of C-PTIO (Figure 2E, F).
Apart from aggregation, nitrite+erythrocytes also inhibited ATP
release from platelets. In the presence of erythrocytes, 0.1 mM
Figure 1. Nitrite had no effect on platelet aggregation in plasma. (A) Nitrite had no effect on ADP and collagen-induced platelet aggregation.
Nitrite was pre-incubated in PRP for 5 min. Platelet aggregation was induced by 8 mM ADP or 2.5 mg/mL collagen. (B) DEANONOate inhibited ADP-
induced platelet aggregation. DEANONOate was pre-incubated in PRP for 5 min. Platelet aggregation was induced by 8 mM ADP. (C) C-PTIO inhibited
the anti-platelet activity of DEANONOate. PRP was incubated with 1 mM DEANONOate and 200 mM C-PTIO for 5 min before the induction of
aggregation by 8 mM ADP. * P,0.05 compared with the others (ANOVA). All experiments were performed at 37uC. Data are means 6 SEM (n$3).
doi:10.1371/journal.pone.0030380.g001
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e30380Figure 2. Nitrite+erythrocytes inhibited platelet aggregation. (A) ADP induced platelet aggregation in PRP+erythrocytes (20% hematocrit) in
the concentration dependent manner. (B) Erythrocytes at 0, 1, 10 and 20% hematocrit did not have effect on ADP-induced platelet aggregation in the
absence of nitrite. (C) Nitrite+erythrocytes (20% hematocrit) inhibited ADP-induced platelet aggregation. Nitrite was incubated in PRP or
PRP+erythrocytes in the presence or absence of 200 mM C-PTIO for 5 min before induction of aggregation by ADP.
*P,0.05 compared with PRP and
PRP+erythrocytes+C-PTIO (ANOVA). (D) The inhibitory effect of 0.1 mM nitrite was dependent on hematocrits. PRP and PRP+erythrocytes (1, 10, and
20% hematocrit) were incubated with 0.1 mM nitrite for 5 min before induction of platelet aggregation by 20 mM ADP. ADP-induced platelet
aggregation in the absence of nitrite was shown in the control group.
*P,0.05 compared with PRP+nitrite at 0% hematocrit (ANOVA). (E)
Nitrite+erythrocytes inhibited collagen-induced platelet aggregation. PRP or PRP+erythrocytes samples (20% hematocrit) were incubated with nitrite
in the presence and absence of 200 mM C-PTIO for 5 min and then the aggregation was induced by 2.5 mg/mL collagen.
*P,0.05 compared with PRP
and PRP+erythrocytes+C-PTIO (ANOVA). (F) Nitrite+erythrocytes inhibited U46619-induced platelet aggregation. 0.1 mM nitrite was incubated in PRP
or PRP+erythrocytes (20% hematocrit) in the presence or absence of 200 mM C-PTIO for 5 min. Then, the aggregation was induced by 1 mM U46619.
*P,0.05 compared with PRP+erythrocytes and PRP+erythrocytes+C-PTIO (ANOVA). All experiments were performed at 37uC. Data are means 6 SEM
(n$3).
doi:10.1371/journal.pone.0030380.g002
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2.5 mg/mL collagen, and 1 mM U46619. C-PTIO completely
inhibited the effect of nitrite+erythrocytes (Figure 3A–C).
In contrast to nitrite, the inhibitory effect of DEANONOate on
platelet aggregation decreased in the presence of erythrocytes.
Erythrocytes at 1% hematocrit attenuated the effect of DEA-
NONOate (Figure 4A, B), presumably due to NO destruction by
hemoglobin in erythrocytes.
Deoxygenation of erythrocytes enhanced the inhibitory
effect of nitrite on platelet activation
Further, we investigated whether the deoxygenation could
enhance the effect of nitrite+erythrocytes on platelet activity. In
the presence of cell-free hemoglobin, the effect of nitrite on
platelets was abolished because nitrite reacted rapidly with free
hemoglobin to form the inactive nitrate ions [12]. Thus, the
washed erythrocytes were prepared freshly to avoid any cell-free
hemoglobin. The erythrocyte suspension was deoxygenated by
helium gas and added into the platelet suspension. Activation of
platelets was induced by 20 mM ADP and determined by the flow
cytometry as an expression of P-selectin (CD62P). The percent-
age of platelets that expressed P-selectin before addition of ADP
was 0.1260.06. After addition of 20 mM ADP, the percentage of
platelets that expressed P-selectin increased to 16.263.7 and
16.664.2 in the presence of oxygenated and deoxygenated
erythrocytes, respectively. Thus, the degree of platelet activation
under oxygenated and deoxygenated condition was not different.
In the presence of erythrocytes (at room air, PO2,57 mmHg),
0.1 and 1 mM nitrite inhibited P-selectin expression. In the
presence of deoxygenated erythrocytes (PO2,25 mmHg), the
effect of 0.1 and 1 mM nitrite increased further to 16.362.4 and
28.764.1% inhibition of P-selectin expression, respectively
(Figure 5A). C-PTIO blocked the effect of nitrite+erythrocytes
on P-selectin expression in the deoxygenated condition. Similarly,
nitrite alone (0.1 mM) had no effect on the cGMP levels in
platelets. Nitrite+erythrocytes increased the cGMP levels in
platelets, and deoxygenation caused further increase in the
cGMP levels (Figure 5B). These results also suggest that the
platelet inhibition by nitrite+erythrocytes was enhanced further
by deoxygenation.
Platelet aggregation in whole blood of volunteers was
correlated with the nitrite levels
To study the potential role of nitrite in the regulation of platelet
activity, we investigated the correlation between the nitrite levels
in blood from 15 healthy donors and platelet aggregation in whole
Figure 3. Nitrite+erythrocytes inhibited ATP release from platelets induced by ADP (A), collagen (B), and U46619 (C).
PRP+erythrocytes (20% hematocrit) were incubated with 0.1 mM nitrite in the presence and absence of 200 mM C-PTIO for 5 min. The ATP release
was induced by 20 mM ADP, 2.5 mg/mL collagen or 1 mM U46619.
*P,0.05 compared with PRP+erythrocytes and PRP+erythrocytes+nitrite+C-PTIO
(ANOVA). All experiments were performed at 37uC. Data are means 6 SEM (n=5).
doi:10.1371/journal.pone.0030380.g003
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blood were measured by tri-iodide based chemiluminescense.
Platelet aggregation in whole blood (20% hematocrit) was induced
by 10 mM ADP and monitored by impedance aggregometry. The
means 6 SEM of the nitrite levels in whole blood, erythrocytes
and plasma were 85.6610.9, 93.4615.1 and 47.267.0 nM,
respectively. The nitrite levels in platelets were 13.664.8 nmol/
10
12 cells. We found the inverse correlations between the extent of
ADP-induced platelet aggregation in whole blood at 5 min and
the nitrite levels in whole blood and erythrocytes (Figure 6A, B).
However, there was no significant correlation between platelet
aggregation and the nitrite levels in either plasma or the platelets.
Discussion
Our results demonstrate the inhibitory effect of nitrite+ery-
throcytes on platelets, but nitrite alone at physiological concen-
trations has no effect on platelets. The effect of nitrite+erythrocytes
on platelet aggregation is inhibited by an NO scavenger,
suggesting that the effect is mediated through NO. Furthermore,
deoxygenation promotes the effect of nitrite+erythrocytes and
causes further increase of the cGMP levels in platelets. This is
likely caused by the nitrite reductase activity of deoxygenated
hemoglobin while a reducing agent such as ascorbic acid did not
have this effect. The inverse correlations between the nitrite levels
in whole blood and erythrocytes with platelet aggregation in
Figure 4. Erythrocytes abolished the effect of DEANONOate on platelet aggregation. (A) Inhibition of platelet aggregation by
DEANONOate decreased in the presence of erythrocytes. PRP and PRP+erythrocytes (20% hematocrit) were incubated with DEANONOate for 5 min.
(B) Dependence of platelet aggregation in the presence of 0.1 mM DEANONOate on hematocrit. PRP and PRP+erythrocytes (1, 10, and 20%
hematocrit) were incubated with 0.1 mM DEANONOate for 5 min. Platelet aggregation was induced by 20 mM ADP. ADP-induced platelet aggregation
in the absence of nitrite was shown in the control group
*P,0.05 compared with 0% hematocrit (ANOVA). All experiments were performed at 37uC.
Data are means 6 SEM (n$3).
doi:10.1371/journal.pone.0030380.g004
Figure 5. Deoxygenation enhanced platelet inhibition by nitrite+erythrocytes. PRP was pre-incubated with nitrite (0.1 or 1 mM) or
nitrite+C-PTIO (200 mM) in the presence of oxygenated or deoxygenated erythrocytes (20% hematocrit) for 5 min. Then, 20 mM ADP was added to the
cell suspension and incubated for 10 min. Platelet activation was determined by the flow cytometry as an expression of P-selectin.
*P,0.05 compared
with the values of oxygenated erythrocytes.
#P,0.05 compared with deoxygenated erythrocytes+C-PTIO (ANOVA). (B) Nitrite+erythrocytes increase
the cGMP levels in platelets. Washed platelets+erythrocyte samples (20% hematocrit) were incubated with 0.1 mM nitrite for 5 min.
*P,0.05
compared with platelets.
#P,0.05 compared with platelets+nitrite+erythrocytes (ANOVA). All experiments were performed at 37uC. Data are means
6 SEM (n$4).
doi:10.1371/journal.pone.0030380.g005
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modulating the baseline platelet activity.
From our results, we conclude that nitrite itself does not inhibit
platelet aggregation induced by ADP, collagen and U46619 in
plasma. This is consistent with a previous study [8] which reports
that nitrite only at high concentration (500 mM) inhibits platelet
aggregation induced by ADP in plasma. However, in the presence
of erythrocytes at 20% hematocrit, the inhibitory activity of nitrite
becomes demonstrable whereas that of DEANONOate decreases.
Because the erythrocytes at hematocrit greater than 20% would
interfere with the impedance aggregometry, the PRP+erythrocytes
at this hematocrit value was used in the subsequent studies. The
20% hematocrit, however, is thought to occur in most vessels of
the microcirculation where much thrombosis occurs and could be
found in large vessels under anemic conditions such as thalassemia
or malaria.
The inhibitory effect of DEANONOate on platelets decreases in
the presence of erythrocytes. This suggests that NO released from
DEANONOate may diffuse rapidly into erythrocytes and then
react with hemoglobin to form inactive nitrate and methemoglo-
bin (k=5 610
7 and 2.6610
7 M
21.s
21 for the reaction of NO with
oxy- and deoxyhemoglobin, respectively) [13,14]. This suggests
that the scavenging of NO by hemoglobin in the erythrocytes may
be responsible for the decreased effect; which is in agreement with
the reports that NO donors such as DEANONOate and S-
nitrosothiol have decreased ability to inhibit platelets in whole
blood [15]. Thus, NO dissociated from NO donor would be taken
up into erythrocytes rapidly and would be unable to escape from
erythrocytes; in contrast to the mechanisms apparently operative
when the NO is generated in the erythrocytes themselves (see
below).
The reaction of nitrite with deoxyhemoglobin would generate
NO because of the nitrite reductase activity of deoxyhemoglobin
[16,17]. Nitrite may enter the erythrocytes in the form of HNO2
via simple or facilitated diffusion through the anion exchanger-1
(AE-1) [18,19,20]. Because deoxyhemoglobin has higher affinity
than oxyhemoglobin in binding AE-1 [21], nitrite is proposed to
react with deoxyhemoglobin located near the cytoplasmic surface
of the erythrocytic membrane. Moreover, the reaction of nitrite
with deoxyhemoglobin bound to AE-1 is faster than that with free
deoxyhemoglobin [22]. Nitrite in erythrocytes reacts with
deoxyhemoglobin to form the iron-nitrosyl-hemoglobin (HbNO)
which is unstable [23,24]. The formation of HbNO is enhanced
under conditions of reduced oxygen saturation. The HbNO could
be oxidized easily by intracellular oxidants such as dehydroascor-
bic acid [24], producing NO or related compounds. Although
most nitrite and NO is scavenged by hemoglobin inside
erythrocytes, some nitrite may react with the deoxyhemoglobin
molecules located near the membrane, leading to the release of
NO or an intermediate such as N2O3 from erythrocytes [25].
However, other mechanisms are possible because of the complex
kinetics of many processes involved.
To examine whether the effect of nitrite was through NO, C-
PTIO was used to inhibit the effect of nitrite on platelet
aggregation. Our results show that C-PTIO diminished the
inhibitory effect of nitrite on platelet aggregation, ATP release
and P-selectin expression. These are consistent with the previous
evidence that vasodilation induced by nitrite in the presence of
erythrocytes is mediated through the generation of extracellular
NO [11]; which is in accordance with the mechanism proposed
above.
The reports that vasodilation induced by nitrite is dependent on
erythrocytes and that deoxyhemoglobin promotes the vasodilatory
effect of nitrite by conversion of nitrite to NO [3,11], led us to
hypothesize further that the deoxygenated erythrocytes would be
involved in the mechanism of platelet inhibition by nitrite. The
inhibitory effect of nitrite+erythrocytes on platelets could be
increased under deoxygenated condition because deoxyhemoglo-
bin possesses the nitrite reductase activity. Our results demonstrate
that deoxygenation enhances the inhibitory effect of nitrite+ery-
throcytes on platelets as observed from a decrease of P-selectin
expression but increase of cGMP levels. Because nitrite does not
activate guanylyl cyclase [26], an increase in cGMP levels in
platelets could result from NO. Therefore, these suggest that NO
produced from the interaction of nitrite with deoxyhemoglobin
may contribute to platelet inhibition. Apart from deoxyhemoglo-
bin, other heme-containing proteins and enzymes, such as
xanthine oxidoreductase, eNOS, and cytochrome P-450 oxidore-
ductase, could be involved in the reduction of nitrite to NO
[27,28].
The correlations between platelet aggregation and nitrite levels
in whole blood and erythrocytes of volunteers suggest the role of
nitrite as one of several factors regulating platelet activity in vivo.
In our experiments, the nitrite levels were measured in fasting
blood to avoid the influence of diet. Despite using the nitrite-
preserving solution, the nitrite concentrations in whole blood,
erythrocytes, and plasma were somewhat lower than those
reported previously for different populations and under different
conditions [29]. Further studies on variation in the nitrite levels in
different population and age groups, and the effects of diet and
other factors remain to be investigated.
In addition, the correlation of blood nitrite and platelet
aggregation also raises the possibility of direct in vivo interactions
between the erythrocytes and platelets. Platelet activity would be
regulated by NO that is produced outside platelets and not from
eNOS within the platelets [30]. The erythrocytes are the major
storage site of nitrite in blood. The erythrocytic nitrite has a half-
life of 10 min in whole blood after drawing [29] and the nitrite
levels would be related to the endothelial eNOS activity via
endothelial function [31]. Thus, the erythrocytic nitrite could
regulate platelet activity by providing NO, especially under
hypoxia. The decreased nitrite levels in blood, as expected in
hemolytic diseases such as sickle cell disease or thalassemia where
Figure 6. Platelet aggregation in whole blood showed inverse
correlation with the nitrite levels in whole blood and
erythrocytes. Platelet aggregation in whole blood (20% hematocrit)
was induced by 10 mM ADP and monitored for 5 min using the
impedance aggregometry. The degree of platelet aggregation was
correlated with the nitrite levels in whole blood (A) and erythrocytes (B).
Each dot represents mean of duplicate measurement (n=15).
doi:10.1371/journal.pone.0030380.g006
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expected to be associated with platelet hyperactivity and vascular
complications [32].
In conclusion, nitrite does not have a direct inhibitory effect on
platelets when studied in plasma. Nonetheless, nitrite+erythrocytes
inhibit platelets through the nitrite reduction to NO; which is
promoted in the deoxygenated condition. Together with vasodi-
lation, the inhibition of platelets by nitrite+erythrocytes could
promote blood flow under hypoxic conditions.
Materials and Methods
Ethics statement
This study was approved by the Ramathibodi Hospital Ethics
Committee. The written informed consent was obtained in
accordance with the Declaration of Helsinki.
Materials
Sodium nitrite (NaNO2), adenosine 59diphosphate (ADP),
collagen, U46619 were purchased from Sigma (St Louis, MO).
Diethylamine diazeniumdiolate (DEANONOate) was purchased
from Cayman Chemical (Ann Arbor, MI). 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazole-1-oxyl 3-oxide (C-PTIO) was pur-
chased from Alexis (Lausen, Switzerland). Luciferin-luciferase
reagent (Chrono-Lume) was purchased from Chrono-Log Corpo-
ration (Howertown, PA). DEANONOate was freshly prepared by
dissolving in 0.01 M NaOH and used within 1 day. Immediately
before use, DEANONOate was diluted in phosphate-buffered
saline (PBS, pH 7.4). Sodium nitrite, ADP, and C-PTIO were
prepared in PBS at pH 7.4. Collagen was prepared in deionized
water.
Monoclonal antibodies: FITC-labeled anti-human CD41a and
PE-labeled anti-human CD62P were purchased from Becton
Dickinson (San Jose, CA).
Healthy volunteers
The volunteers had been in fasting state for at least 8 h. The
fasting venous blood samples were taken from healthy volunteers,
of 28.064.1 (mean 6 SD) years of age, and placed in tubes
containing 3.8% sodium citrate in the ratio of 9:1 (vol/vol). The
volunteers were non-smokers and had not taken nonsteroidal anti-
inflammatory drug within a week or other medications within
48 h.
Platelet aggregation and ATP release
Whole blood was centrifuged at 1206g for 10 min at room
temperature. The upper portion was collected for PRP. The lower
portion was centrifuged further at 20006g for 10 min to obtain
the platelet-poor plasma (PPP). The PRP was used for aggregation
studies within 2 h after blood drawing. The effect of sodium nitrite
on platelet aggregation in PRP and PRP+erythrocytes was
determined by the turbidimetric and impedance aggregometry,
respectively.
In turbidimetric experiments, the PRP was pre-incubated with
0.01–100 mM sodium nitrite or DEANONOate at 37uC for
5 min. In separate experiments, the PRP was pre-incubated with
1 mM DEANONOate for 5 min in the presence or absence of
200 mM C-PTIO. Platelet aggregation was induced by 8 mM ADP
or 2.5 mg/mL collagen. ADP at 8 mM, which was the lowest
concentrations that caused irreversible platelet aggregation, was
used in the subsequent experiment in PRP. Platelet aggregation
was monitored by the Aggregometer Model 500/560 CA
(Chrono-Log Corporation, Howertown, PA) for 4 min at 37uC.
The increased light transmission indicated increased aggregation
in PRP.
In impedance experiments, platelet aggregation in PRP or
PRP+erythrocytes was studied by impedance aggregometry in
which the change of electrical impedance (in ohm, V) was
monitored. The increase of the electrical impedance of electrode
correlated with the aggregation. The aggregation was induced by
20 mM ADP, 2.5 mg/mL collagen or 1 mM U46619 and recorded
for 5 min at 37uC. Because the pre-incubation of nitrite+ery-
throcytes in PRP for 5 min caused the stable maximal inhibition of
aggregation, the 5-min duration of incubation was used in the
subsequent aggregation studies. To prepare the erythrocytes, the
whole blood was centrifuged at 20006g for 10 min. The plasma
and buffy coat were carefully removed to obtain the packed
erythrocytes. The erythrocytes were added into PRP to produce
different hematocrits. The hematocrit values in the mixture of
PRP+erythrocytes were checked by the microhematocrit centri-
fuge. The PRP+erythrocyte samples were pre-incubated at 37uC
with 0.01–10 mM sodium nitrite or DEANONOate for 5 min in
the presence or absence of C-PTIO.
The ATP released from platelets was monitored by lumines-
cence aggregometer using a luciferin-luciferase assay. The amount
of ATP was calculated from the luminescence signal of ATP
standard according to the manufacturing protocol.
Flow cytometry
The influence of deoxygenation on platelet inhibition by
nitrite+erythrocytes was studied by flow cytometry. The erythro-
cytes were washed three times with an equal volume of PBS and
then diluted with PBS to obtain 50% hematocrit. The oxygen
saturation in erythrocytes was decreased by helium blown above
the cell suspension with gentle stirring for 30 min. As measured by
a blood gas analyzer (Stat Profile Critical Care Xpress, Nova
Biomedical, Waltham, MA), the deoxygenated erythrocytes
contained PO2 25 mmHg and SO2 44% while the erythrocytes
at room air contained PO2 57 mmHg and SO2 84%. The
deoxygenated erythrocytes were stored in vacuum container at
4uC until used within 12 h.
All reagent solutions were deoxygenated by helium gas. The
PRP was diluted 1:4 (vol/vol) by deoxygenated PBS. 100 mL of the
diluted PRP was gently pipetted into a sealed cuvette inside a
deoxygenated glovebox. The erythrocytes were added into the
cuvette to obtain 20% hematocrit. Afterwards, 0.1 or 1 mM nitrite
in the presence or absence of 200 mM C-PTIO was added into the
cell suspension. The mixture was incubated at 37uC for 5 min.
Then, 20 mM ADP was added into each cuvette and incubated in
the mixture for 10 min at 37uC. To prevent further progress of
platelet activation, 100 mL of samples were fixed with 1%
paraformaldehyde at 4uC for 2 h. 10 mL of sample was added
into a tube containing saturated concentration of FITC-labeled
CD41a and PE-labeled CD62P. The samples were incubated in
dark at room temperature for 15 min and analyzed on a FACScan
flow cytometry (Becton Dickinson, Oxford, U.K.). The platelets
were distinguished by the characteristic of light scatter and
antibody to platelet CD41a. The baseline levels of P-selectin
(CD62P) expression, a platelet degranulation marker, were
quantified in samples without ADP and used as a reference for
subsequent experiments. A percentage of cells with CD62P
expression greater than the baseline levels was calculated from
2000 events positive for CD41a.
Measurement of cGMP levels in platelets
Washed platelets were prepared from PRP [33]. After washing,
the pellet was resuspended in the incubation buffer (134 mM
Platelet Inhibition by Nitrite and Erythrocytes
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1 mM CaCl2, 0.8 mM MgCl2, 5 mM Hepes, 5 mM glucose,
pH 7.4). The number of washed platelets was adjusted to 3610
8
cells/mL and incubated for 1 h at room temperature before use.
0.1 mM nitrite was added into the platelet suspension in the
presence or absence of erythrocytes (20% hematocrit). After
incubation with agonist and stirring at 37uC for 5 min, the samples
were mixed with 5% trichloroacetic acid and centrifuged at
15006g for 10 min. The supernatant was collected and stored at
280uC until measurement. The cGMP levels were measured by
the enzyme-linked immunoassay (Cayman Chemical, Ann Arbor,
MI).
Measurement of nitrite in blood
The nitrite levels in whole blood, erythrocytes, plasma, and
platelets were measured. The fasting venous blood was collected
using 3.8% sodium citrate as an anticoagulant. Because nitrite has
half-life of 10 min after blood drawing at room temperature, the
whole blood were mixed immediately with the nitrite-stabilizing
solution and stored at 280uC [29]. In a separate set of
experiments, the whole blood was centrifuged immediately at
20006g for 1 min at 4uC to obtain the packed erythrocytes and
plasma. The erythrocytes were immediately mixed with the nitrite-
preserving solution within 2 min after blood drawing. The nitrite
levels were measured specifically by tri-iodide based chemilumi-
nescence [29,34] using the chemiluminescence NO analyzer. To
measure the nitrite levels in platelets, the whole blood was
centrifuged for 1206ga t4 uC for 10 min to obtain PRP. The PRP
was collected and re-centrifuged at 15006g to obtain the platelet
pellet. The platelet pellet was resuspended in 200 mL of PBS
before injection into the tri-iodide solution. The nitrite levels in
platelets were calculated following subtraction of the nitrite levels
in PBS from the levels in platelet suspension.
Statistical analysis
All data are means 6 SEM. Data processing and statistical
analysis were analyzed by GraphPad PrismH version 4 (GraphPad
software Inc., San Diego, CA). Correlation was analyzed by
Pearson’s method. ANOVA with Tukey’s multiple comparison
were used to compare with acceptable P-value,0.05.
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